{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:42:44Z","timestamp":1761176564819,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.radonc.2025.110946","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T03:40:35Z","timestamp":1747798835000},"page":"110946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design and pre-trial dose planning quality assurance of the Nordic trial of inhomogeneous dose escalated radiotherapy for patients with limited disease small cell lung cancer: NIELS"],"prefix":"10.1016","volume":"209","author":[{"given":"Sara","family":"Linde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ditte S.","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai-Britt","family":"Linaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ane","family":"Appelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Almhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth F.","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne M.","family":"Knap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotte H.","family":"Land","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel D.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Merring-Mikkelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tine B.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiviann","family":"Ottosson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitte F.","family":"Persson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hella M.B.","family":"Sand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten H.","family":"Suppli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Villegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hj\u00f8rdis H.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weronika M.","family":"Szejniuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lone","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110946_b0005","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/cncr.35444","article-title":"Global cancer statistics 2022","volume":"130","author":"Nierengarten","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.110946_b0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>\u2606<\/sup>","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110946_b0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(20)30742-7","article-title":"High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"22","author":"Gronberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0025","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.21037\/tlcr.2019.05.13","article-title":"Recent developments in limited stage small cell lung cancer","volume":"8","author":"Higgins","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.radonc.2025.110946_b0030","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3109\/0284186X.2015.1062135","article-title":"Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy","volume":"54","author":"Winther-Larsen","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0035","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0040","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.radonc.2017.07.019","article-title":"Patterns of failure in limited-stage small cell lung cancer: implications of TNM stage for prophylactic cranial irradiation","volume":"125","author":"Wu","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.radonc.2025.110946_b0050","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/02841860701316065","article-title":"Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004","volume":"46","author":"Hallqvist","year":"2007","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0055","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.1997.15.3.893","article-title":"Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study","volume":"15","author":"Jeremic","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S2213-2600(24)00189-9","article-title":"High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial","volume":"12","author":"Yu","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.radonc.2025.110946_b0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109492","article-title":"(18)F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial","volume":"181","author":"Cooke","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0075","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.radonc.2017.06.022","article-title":"Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): design and early dosimetric results of a randomized, multi-centre phase-III study","volume":"124","author":"Moller","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0080","doi-asserted-by":"crossref","unstructured":"Schytte T et al. Toxicity within 6 months of heterogeneous fluorodeoxyglucose-guided radiotherapy dose escalation for locally advanced non\u2013small cell lung cancer in the Scandinavian randomized phase III NARLAL2 trial. J Clin Oncol 0(0):JCO-24-01386. https:\/\/doi.org\/10.1200\/jco-24-01386.","DOI":"10.1200\/JCO-24-01386"},{"key":"10.1016\/j.radonc.2025.110946_b0085","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S1470-2045(23)00625-3","article-title":"Radiotherapy trial quality assurance processes: a systematic review","volume":"25","author":"Brooks","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0090","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jnci\/djt001","article-title":"Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials","volume":"105","author":"Ohri","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2025.110946_b0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.radonc.2022.04.005","article-title":"Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours","volume":"171","author":"Hoffmann","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0169-5002(89)90156-6","article-title":"Staging and prognostic factors in small cell lung cancer: a consensus report","volume":"5","author":"Stahel","year":"1989","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2025.110946_b0105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.110946_b0110","doi-asserted-by":"crossref","first-page":"S3005","DOI":"10.1016\/S0167-8140(24)01066-1","article-title":"448: National consensus-based bespoke automatic delineation of thoracic organs at risk","volume":"194","author":"Thorsen","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.semradonc.2003.10.003","article-title":"Errors and margins in radiotherapy","volume":"14","author":"van Herk","year":"2004","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijrobp.2005.05.045","article-title":"Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer","volume":"63","author":"Underberg","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110946_b0125","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1080\/0284186X.2017.1373848","article-title":"Difference in target definition using three different methods to include respiratory motion in radiotherapy of lung cancer","volume":"56","author":"Sloth M\u00f8ller","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.radonc.2020.07.012","article-title":"ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer","volume":"152","author":"Le Pechoux","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0135","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.radonc.2012.10.006","article-title":"Bioeffect modeling and equieffective dose concepts in radiation oncology\u2013terminology, quantities and units","volume":"105","author":"Bentzen","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0140","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ijrobp.2010.07.1977","article-title":"Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus","volume":"81","author":"Kong","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110946_b0145","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.ijrobp.2014.08.348","article-title":"Global harmonization of quality assurance naming conventions in radiation therapy clinical trials","volume":"90","author":"Melidis","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110946_b0150","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/489\/1\/012100","article-title":"A DICOM based radiotherapy plan database for research collaboration and reporting","volume":"489","author":"Westberg","year":"2014","journal-title":"J Phys Conf Ser"},{"key":"10.1016\/j.radonc.2025.110946_b0155","doi-asserted-by":"crossref","first-page":"N337","DOI":"10.1088\/0031-9155\/55\/11\/N04","article-title":"Comparison of DVH data from multiple radiotherapy treatment planning systems","volume":"55","author":"Ebert","year":"2010","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2025.110946_b0160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.radonc.2021.11.018","article-title":"The radiotherapy quality assurance gap among phase III cancer clinical trials","volume":"166","author":"Corrigan","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009849","volume":"6","author":"Faivre-Finn","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.radonc.2025.110946_b0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.radonc.2021.07.017","article-title":"Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial","volume":"163","author":"Gkika","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.radonc.2018.10.025","article-title":"Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark case results","volume":"132","author":"Lambrecht","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0180","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijrobp.2024.03.045","article-title":"Evaluation of radiation therapy treatment plans in a randomized phase 2 trial comparing 2 schedules of twice-daily thoracic radiation therapy in limited stage small cell lung cancer","volume":"120","author":"Levin","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110946_b0185","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2017.07.053","article-title":"Radiation dose to heart base linked with poorer survival in lung cancer patients","volume":"85","author":"McWilliam","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.110946_b0190","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamaoncol.2020.6332","article-title":"Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer","volume":"7","author":"Atkins","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110506","article-title":"Daily CBCT-based dose calculations for enhancing the safety of dose-escalation in lung cancer radiotherapy","volume":"200","author":"Thomsen","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110946_b0200","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/0284186X.2017.1366049","article-title":"The NARLAL2 dose escalation trial: dosimetric implications of inter-fractional changes in organs at risk","volume":"57","author":"Hoffmann","year":"2018","journal-title":"Acta Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025044500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025044500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:20:21Z","timestamp":1761128421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025044500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"alternative-id":["S0167814025044500"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110946","relation":{},"ISSN":["0167-8140"],"issn-type":[{"type":"print","value":"0167-8140"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and pre-trial dose planning quality assurance of the Nordic trial of inhomogeneous dose escalated radiotherapy for patients with limited disease small cell lung cancer: NIELS","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110946"}}